–2Q rev/np +1%/3%; all eyes on cost savings
Eyes on monetization potential and margin improvement trajectory
All eyes on 4Q24E for the room of re-rating
–Eye on upcoming launch of Twist of the Fate
An Eye on Methane: International Methane Emissions Observatory 2023 Report
Eyes on post-COVID business recovery
–Eyes on the FDA approval of fruquintinib in Nov
China Technology–Global fabless/IDM 2Q23 wrap: expect continued inventory correction for non-AI players; All eyes on NVDA 3Q23E guidance
–Eye on GAP revitalization & livestreaming ecommerce expansion
Eyeing on the pace of fundamental recovery post sentiment rebound